Clinical Policy: Pancreas Transplantation
Reference Number: CP.MP.102
Date of Last Revision: 02/23

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
This policy describes the medical necessity requirements for pancreas transplantation procedures. Multiple types of pancreas transplants are effective therapeutic options for arresting the progression of complications of diabetes mellitus and improving the quality of life for diabetic patients, including simultaneous pancreas kidney transplant (SPK), pancreas after kidney transplant (PAK), pancreas transplant alone (PTA), and islet cell transplant.¹

Note: For criteria related to Lantidra, please see CP.MP.250 Lantidra (donislecel): Allogeneic Pancreatic Islet Cellular Therapy

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation® that pancreas transplantation is medically necessary when meeting all of the following:
   A. Member/enrollee has one of the following:
      1. Diagnosis of diabetes mellitus requiring insulin (members/enrollees with requirements for insulin over one unit/kg should be closely evaluated as they may be less likely to benefit from pancreas transplant compared to those with lower insulin doses);
      2. Diagnosis of exocrine pancreatic insufficiency;
      3. A requirement for the procurement or transplantation of a pancreas as part of a multiple organ transplant for technical reasons;
   B. Does not have ANY of the following contraindications:²,⁸
      1. Malignancy with high risk of recurrence or death related to cancer;
      2. Glomerular filtration rate < 40 mL/min/1.73m² unless being considered for multi-organ transplant;
      3. Stroke, acute coronary syndrome, or myocardial infarction (excluding demand ischemia) within 30 days;
      4. Acute liver failure, or cirrhosis with portal hypertension or synthetic dysfunction unless being considered for multi-organ transplant;
      5. Septic shock;
      6. Active infection with highly virulent and/or resistant microbes that are poorly controlled pre-transplant;
      7. Active tuberculosis infection;
      8. HIV infection with detectable viral load;
      9. Progressive cognitive impairment;
      10. Inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support;
      11. Active substance use or dependence including current tobacco use, vaping, marijuana use (unless prescribed by a licensed practitioner), or IV drug use without convincing evidence of risk reduction behaviors (unless urgent transplant timelines are present, in
C. Request is for one of the following procedures and meets the corresponding criteria:

1. Pancreas Transplant Alone (PTA), meets all:
   a. Recurrent, severe, and potentially life-threatening metabolic complications that require medical attention, as documented by chart notes, emergency room visits, or hospitalizations, including any of the following:
      i. Severe hypoglycemia unawareness;
      ii. Marked hyperglycemia;
      iii. Recurring severe ketoacidosis;
   b. Clinical or clinical and emotional problems with exogenous insulin therapy that are so severe as to be incapacitating or consistent failure of insulin-based management to prevent acute complications;
   c. Has been medically managed by an endocrinologist for at least 12 months;

2. Simultaneous Pancreas Kidney Transplant (SPK), meets all:
   a. Meets above criteria for PTA;
   b. End-stage renal disease (ESRD), as defined by both:
      i. Presence of uremia;
      ii. Requires dialysis or is expected to require dialysis in the next 12 months;
   c. Glomerular filtration rate (GFR) ≤ 20mL/min (does not have to be the most recent value) or creatinine clearance (CrCl) < 20mL/min;

3. Pancreas After Kidney Transplant (PAK), meets all:
   a. Meets above criteria for PTA;
   b. Underwent successful kidney transplant without significant chronic rejection of kidney transplant;
   c. Stable kidney transplant function, as defined by both:
      i. Stable creatinine clearance ≥ 30 mL/min;
      ii. Absence of significant proteinuria.

II. It is the policy of health plans affiliated with Centene Corporation that autologous islet cell transplants are considered medically necessary as an adjunct procedure to a total or near total pancreatectomy for severe, refractory pancreatitis.

III. It is the policy of health plans affiliated with Centene Corporation that pancreas re-transplantations are considered medically necessary after one failed primary pancreas transplant.

IV. It is the policy of health plans affiliated with Centene Corporation that current evidence does not support the use of pancreas transplant procedures for any of the following indications:
   A. Re-transplantations after two or more failed primary pancreas transplantations;
   B. Allogeneic islet cell transplantation or xenotransplantation;
C. SPK transplantation for patients with amputation due to peripheral obstructive vascular disease;
D. For the treatment of all other conditions than those specified above.

Background
The American Diabetes Association defines diabetes mellitus as a group of metabolic diseases characterized by hyperglycemia that results from defects in insulin secretion, insulin action, or both. According to the Centers for Disease Control and Prevention estimations, approximately 37.3 million people or 11.3% of the United States population has diabetes with approximately 8.5 million undiagnosed cases. Chronic hyperglycemia existing in diabetic patients facilitates long term organ damage, especially to the eyes, kidneys, nerves, and blood vessels.

The prevalent type 2 diabetes is caused by a resistance to insulin action and an inadequate compensatory insulin secretory response. Type 1 diabetes is caused by immune mediated destruction of the insulin secreting pancreatic β cells. Islet cell autoantibodies, insulin autoantibodies, autoantibodies to glutamic acid decarboxylase, zinc transporter 8 (ZnT8A), and autoantibodies to the tyrosine phosphatase IA-2 and IA-2β are serological markers of the pancreatic β cell destruction observed in type 1 diabetes.

Pancreas transplantation allows for the possibility to restore glucose regulated endogenous secretion, decrease the progression of diabetic complications, and improve quality of life in patients with diabetes. Pancreas transplantation is the only proven method to restore normoglycemia in type 1 diabetic patients. Simultaneous pancreas kidney transplant (SPK), pancreas after kidney transplant (PAK), and pancreas transplant alone (PTA) are primarily performed on patients with type 1 diabetes. SPK is an established procedure for diabetic patients with advanced chronic kidney disease or end stage kidney disease and accounts for approximately 90% of pancreas transplants performed in the United States.

A 2011 study by Gruessner reviewed the outcomes of SPK, PAK, and PTA transplantations according to follow-up data collected by the International Pancreas Transplant Registry. Patient survival rates were reported to be over 95% after one year and over 83% at five years post-transplant. The highest graft survival rates were observed in SPK transplants at 86% for pancreas and 93% for kidney graft function one year post-transplant. PAK procedures displayed graft function at 80%, while PTA had graft function at 78% one year after transplantation. Graft survival rate is defined as total freedom from insulin therapy, normal fasting blood glucose concentrations, and normal or only slightly elevated hemoglobin A1C values. The study demonstrated that pancreas transplantation offers excellent outcomes for patients with labile diabetes due to the improvement in patient survival and graft function shown in all three categories over the course of 24 years.

Patients undergoing pancreas transplantation, especially SPK transplant, require extensive immunosuppression regiments. It is theorized that pancreas transplant recipients require higher levels of immunosuppression therapy than other solid organ transplants due to the immunogenicity of the pancreas or the autoimmune status of the recipient.

During pancreatic islet autotransplantation, Islet β cells are transferred into the liver through the portal vein of the recipient. Pancreatic islet autotransplantation is performed following a
Pancreatectomy in patients with severe chronic pancreatitis. Chronic pancreatitis is a debilitating disease which causes diarrhea, weight loss, poor quality of life, and severe abdominal pain that is difficult to alleviate with pharmacological treatment or other therapeutic measures. Due to the excessive pain observed in patients with chronic pancreatitis, pain control is a primary goal of pancreatectomy and pancreatic islet autotransplantation.

Coding Implications
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT Codes that support coverage criteria

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>48160</td>
<td>Pancreatectomy, total or subtotal, with autologous transplantation of pancreas of pancreatic islet cells</td>
</tr>
<tr>
<td>48550</td>
<td>Donor pancreatectomy (including cold preservation), with or without duodenal segment for transplantation</td>
</tr>
<tr>
<td>48551</td>
<td>Backbench standard preparation of cadaver donor pancreas allograft prior to transplantation, including dissection of allograft from surrounding soft tissues, splenectomy, duodenotomy, ligation of bile duct, ligation of mesenteric vessels, and Y-graft arterial anastomoses from iliac artery to superior mesenteric artery and to splenic artery</td>
</tr>
<tr>
<td>48552</td>
<td>Backbench reconstruction of cadaver donor pancreas allograft prior to transplantation, venous anastomosis, each</td>
</tr>
<tr>
<td>48554</td>
<td>Transplantation of pancreatic allograft</td>
</tr>
<tr>
<td>48556</td>
<td>Removal of transplanted pancreatic allograft</td>
</tr>
<tr>
<td>50300</td>
<td>Donor nephrectomy (including cold preservation); from cadaver donor, unilateral or bilateral</td>
</tr>
<tr>
<td>50320</td>
<td>Donor nephrectomy (including cold preservation); open, from living donor</td>
</tr>
<tr>
<td>50323</td>
<td>Backbench standard preparation of cadaver donor renal allograft prior to transplantation, including dissection and removal of perinephric fat, diaphragmatic and retroperitoneal attachments, excision of adrenal gland, and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary</td>
</tr>
<tr>
<td>50325</td>
<td>Backbench standard preparation of living donor renal allograft (open or laparoscopic) prior to transplantation, including dissection and removal of perinephric fat and preparation of ureter(s), renal vein(s), and renal artery(s), ligating branches, as necessary</td>
</tr>
<tr>
<td>50327</td>
<td>Backbench reconstruction of cadaver or living donor renal allograft prior to transplantation; venous anastomosis, each</td>
</tr>
<tr>
<td>50340</td>
<td>Recipient nephrectomy (separate procedure)</td>
</tr>
<tr>
<td>50360</td>
<td>Renal allotransplantation, implantation of graft; without recipient nephrectomy</td>
</tr>
</tbody>
</table>
CPT® Codes | Description
---|---
50365 | Renal allotransplantation, implantation of graft; with recipient nephrectomy

**CPT Codes that do not support coverage criteria**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0584T</td>
<td>Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous</td>
</tr>
<tr>
<td>0585T</td>
<td>Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic</td>
</tr>
<tr>
<td>0586T</td>
<td>Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open</td>
</tr>
</tbody>
</table>

**HCPCS Codes**

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>S2065</td>
<td>Simultaneous pancreas kidney transplantation</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Policy developed. Reviewed by specialist 4/16.</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/16</td>
<td>04/16</td>
<td></td>
</tr>
<tr>
<td>References reviewed and updated</td>
<td>03/17</td>
<td>03/17</td>
</tr>
<tr>
<td>Removed “islet cell transplantation” from III. References reviewed and updated. ICD-10 and HCPCS codes added.</td>
<td>01/18</td>
<td>02/18</td>
</tr>
<tr>
<td>Minor wording changes to description for clarity</td>
<td>05/18</td>
<td></td>
</tr>
<tr>
<td>Added “early prostate cancer with a low Gleason score,” as an exception to malignancy contraindication, I.b. Removed “and/or islet cell” from IV. A. References reviewed and updated. Specialist reviewed.</td>
<td>01/19</td>
<td>02/19</td>
</tr>
<tr>
<td>References reviewed and updated. In I.D.2.b for SPK, changed GFR “&lt;20” to GFR “≤ 20”. Added 2020 CPT codes that do not support coverage criteria (0584T, 0585T, 0586T) Added ICD-10 Z94.83</td>
<td>01/20</td>
<td>02/20</td>
</tr>
<tr>
<td>Edited malignancy contraindication to not specify within 2 years, or low Gleason score, and added exceptions early stage prostate cancer, cancer that has been completely resected, or that has been treated and poses acceptable future risk. Clarified that BMI maximal allowable value in I.B. 2 is (i.e., &lt; 30 to 35 kg/m2, depending on transplant center).</td>
<td>05/20</td>
<td>05/20</td>
</tr>
<tr>
<td>Background updated to reflect current data. References reviewed and updated. Replaced “member” with “member/enrollee” in all instances. Under contraindication I.C. removed “malignancy metastasized to or extending beyond the margins of the kidney and/or pancreas” as this is inclusive to contraindication #1.</td>
<td>01/21</td>
<td>02/21</td>
</tr>
</tbody>
</table>
## Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Removed contraindication of “severely limited functional status with poor rehabilitation potential.” Replaced “Psychiatric or psychological condition associated with the inability to cooperate or comply with medical therapy” and the contraindication regarding non-compliance with medical therapy with “Inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support.” Changed “Review Date” in header to “Date of Last Revision,” and “Date” in the revision log header to “Revision Date.”</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/21</td>
<td>08/21</td>
<td></td>
</tr>
</tbody>
</table>

**Annual review. References reviewed and updated. Updated description and background with no clinical significance. Removed requirement in I.A. that medical therapy does not exist or has failed. Updated all contraindications in criteria I.C. “Experimental/investigational” verbiage replaced in criteria IV. statement with descriptive language. Specialist reviewed.**

<table>
<thead>
<tr>
<th>Annual review. Removed criterion I.A. stating that medical treatment does not exist or has failed. Removed C-peptide values and BMI requirements from Criteria I.B.1 and I.B.2. Noted in I.B.1. that member/enrollees with requirements for insulin over one unit/kg should be closely evaluated as they may be less likely to benefit from pancreas transplant compared to those with lower insulin doses Added indication in I.B.2 for exocrine pancreatic insufficiency. Added indication I.B.3. for requirement for the procurement or transplantation of a pancreas as part of a multiple organ transplant for technical reasons; Changed “chronic” to “active” in infection contraindication in I.C.7. Removed acute renal failure contraindication. Criteria I.C.12. updated to exclude marijuana use when prescribed by a licensed practitioner and include required commitment to reducing substance use behaviors if urgent transplant timelines are present. Added chronic, non-healing wounds as contraindication in Criteria I.C.13. Added contraindication of significant comorbidities in Criteria I.C.14. Clarified in I.C.1.b that problems with insulin could be clinical or clinical and emotional. Added in I.C.2.c. that the GFR does not have to be the most recent value. Added Criteria I.D.1.c. requirement for being medically managed by an endocrinologist for at least 12 months for pancreas transplant alone. Added requirements for SPK and PAK that PTA criteria also needs to be met for those procedures. ICD-10 codes removed. Background updated with no impact on criteria. References reviewed and updated.</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/22</td>
<td>02/22</td>
<td></td>
</tr>
<tr>
<td>02/23</td>
<td>02/23</td>
<td></td>
</tr>
</tbody>
</table>

**Added note to policy to see CP.MP.250 Lantidra (donislecel): Allogeneic Pancreatic Islet Cellular Therapy for criteria related to Lantidra.**

<table>
<thead>
<tr>
<th>Additional references to criteria related to Lantidra.</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/23</td>
<td>08/23</td>
<td></td>
</tr>
</tbody>
</table>

## References


Clinical Policy
Pancreas Transplantation


Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional...
CLINICAL POLICY
Pancreas Transplantation

organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.
**Clinical Policy**

Pancreas Transplantation

**Note:** For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCD’s and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov) for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.